| P2093 | author name string | Freyer G | |
| | Trillet-Lenoir V | |
| | Tranchand B | |
| | Serre-Debeauvais F | |
| | Ligneau B | |
| | Ardiet C | |
| P2860 | cites work | Prediction of carboplatin clearance from standard morphological and biological patient characteristics | Q72241637 |
| | Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors | Q72327079 |
| | Relationship between fluorouracil systemic exposure and tumor response and patient survival | Q72504290 |
| | Phase I and pharmacokinetic trial of weekly CPT-11 | Q72576855 |
| | Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer | Q72970794 |
| | Prediction of creatinine clearance from serum creatinine | Q29615603 |
| | Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer | Q33363246 |
| | Carboplatin dosage: prospective evaluation of a simple formula based on renal function | Q33429552 |
| | 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer | Q36467110 |
| | A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients | Q36468048 |
| | Pharmacodynamics in cancer therapy | Q37963299 |
| | Pharmacokinetic drug interactions of commonly used anticancer drugs. | Q38164714 |
| | Interaction of anticancer drugs with hepatic monooxygenase enzymes | Q38709449 |
| | Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity | Q39647429 |
| | The clinical pharmacology of methotrexate.new applications of an old drug | Q39716312 |
| | Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity | Q40655039 |
| | Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials | Q40995855 |
| | Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer | Q41450904 |
| | Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity | Q41774519 |
| | Etoposide kinetics in patients with obstructive jaundice | Q42050531 |
| | Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours | Q42218659 |
| | Can severe vincristine neurotoxicity be prevented? | Q42241620 |
| | Limited sampling models for doxorubicin pharmacokinetics | Q43776363 |
| | Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity | Q44317117 |
| | Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule | Q48590767 |
| | Bayesian estimation of doxorubicin pharmacokinetic parameters | Q52465225 |
| | Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. | Q52677128 |
| | High-dose methotrexate: a clinical and pharmacokinetic evaluation. Treatment of advanced squamous cell carcinoma of the head and neck using a prospective mathematical model and pharmacokinetic surveillance. | Q52727612 |
| | Some suggestions for measuring predictive performance | Q52875851 |
| | CLINICAL CALORIMETRY | Q56391094 |
| | Joint NCI-EORTC consensus meeting on neoplasia in the elderly | Q60685508 |
| | Pharmacokinetics in clinical practice. I. Concepts | Q67771284 |
| | Relation of systemic exposure to unbound etoposide and hematologic toxicity | Q68004991 |
| | Doxorubicin clearance in the obese | Q68489640 |
| | Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect | Q68719349 |
| | Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia | Q68759827 |
| | Methotrexate test-dose protocol in the presence of 7-hydroxy-methotrexate | Q68773256 |
| | Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution | Q69361463 |
| | 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity | Q69400956 |
| | Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin | Q69579802 |
| | Biological age versus physical fitness age | Q69638066 |
| | High-dose melphalan dosage adjustment: possibility of using a test-dose | Q69936122 |
| | A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve | Q70997291 |
| | Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer | Q71692731 |
| | Test dose for predicting high-dose methotrexate infusions | Q71727462 |
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 153-169 | |
| P577 | publication date | 1997-05-01 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice | |
| P478 | volume | 23 | |